IART — Integra LifeSciences Holdings Share Price
0.000.00%
Last trade - 00:00- $1.30bn
- $2.83bn
- $1.61bn
- 55
- 65
- 80
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.61 | ||
| PEG Ratio (f) | 0.18 | ||
| EPS Growth (f) | 57.91% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.84 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 86.51 | ||
| Price to Sales | 0.81 | ||
| EV to EBITDA | 16.73 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.9% | ||
| Return on Equity | -0.44% | ||
| Operating Margin | 1.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,371.87 | 1,542.45 | 1,557.67 | 1,541.57 | 1,610.53 | 1,679.52 | 1,751.85 | 1.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -3.48 | +6.18 | +14.9 | -8.24 | -51.8 | +102.79 | +10.4 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Directors
- Stuart Essig CHM (58)
- Jan De Witte PRE (57)
- Carrie Anderson CFO (52)
- Glenn Coleman COO (53)
- Lisa Evoli CHO (51)
- Eric Schwartz EVP (52)
- Robert Davis EVP (62)
- Michael Mcbreen EVP (55)
- Jeffrey Mosebrook SVP (44)
- Barbara Hill LED (68)
- Rhonda Ballintyn IND (64)
- Keith Bradley IND (76)
- Shaundra Clay IND (50)
- Donald Morel IND (64)
- Raymond Murphy IND (73)
- Christian Schade IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 19th, 1989
- Public Since
- August 16th, 1995
- No. of Shareholders
- 753
- No. of Employees
- 4,396
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 77,249,944
- Address
- 1100 Campus Road, PRINCETON, 08540
- Web
- https://www.integralife.com/
- Phone
- +1 6092750500
- Contact
- Chris Ward
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for IART
Q1 2025 Integra Lifesciences Holdings Corp Earnings Release
Integra Lifesciences Holdings Corp Annual Shareholders Meeting
Integra LifeSciences Holdings Corp Annual Shareholders Meeting
Q2 2025 Integra Lifesciences Holdings Corp Earnings Release
Similar to IART
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Integra LifeSciences Holdings share price?
As of Today at 21:20 UTC, shares in Integra LifeSciences Holdings are trading at $16.81. This share price information is delayed by 15 minutes.
How has the Integra LifeSciences Holdings share price performed this year?
Shares in Integra LifeSciences Holdings last closed at $16.81 and the price had moved by -40.83% over the past 365 days. In terms of relative price strength the Integra LifeSciences Holdings share price has underperformed the S&P500 Index by -45.38% over the past year.
What are the analyst and broker recommendations for Integra LifeSciences Holdings?
The overall consensus recommendation for Integra LifeSciences Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Integra LifeSciences Holdings dividend yield?
Integra LifeSciences Holdings does not currently pay a dividend.
Does Integra LifeSciences Holdings pay a dividend?
Integra LifeSciences Holdings does not currently pay a dividend.
When does Integra LifeSciences Holdings next pay dividends?
Integra LifeSciences Holdings does not currently pay a dividend.
How do I buy Integra LifeSciences Holdings shares?
To buy shares in Integra LifeSciences Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Integra LifeSciences Holdings?
As of the previous close price of $16.81, shares in Integra LifeSciences Holdings had a market capitalisation of $1.30bn.
Where are Integra LifeSciences Holdings shares listed?
Here are the trading details for Integra LifeSciences Holdings:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IART
What kind of share is Integra LifeSciences Holdings?
Based on an overall assessment of its quality, value and momentum Integra LifeSciences Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Integra LifeSciences Holdings share price forecast for 2025?
The analyst consensus target price for shares in Integra LifeSciences Holdings is $24.75. That is 47.23% above the last closing price of $16.81.
Analysts covering Integra LifeSciences Holdings currently have a consensus Earnings Per Share (EPS) forecast of $2.46 for the next financial year.
Find out moreWhat is the trend in the Integra LifeSciences Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Integra LifeSciences Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -6.5%.
As of the last closing price of $16.81, shares in Integra LifeSciences Holdings were trading -24.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Integra LifeSciences Holdings PE Ratio?
The Integra LifeSciences Holdings PE ratio based on its reported earnings over the past 12 months is 6.61. The shares last closed at $16.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Integra LifeSciences Holdings?
Integra LifeSciences Holdings' management team is headed by:
- Stuart Essig - CHM
- Jan De Witte - PRE
- Carrie Anderson - CFO
- Glenn Coleman - COO
- Lisa Evoli - CHO
- Eric Schwartz - EVP
- Robert Davis - EVP
- Michael Mcbreen - EVP
- Jeffrey Mosebrook - SVP
- Barbara Hill - LED
- Rhonda Ballintyn - IND
- Keith Bradley - IND
- Shaundra Clay - IND
- Donald Morel - IND
- Raymond Murphy - IND
- Christian Schade - IND